NASDAQ:ABUS Arbutus Biopharma (ABUS) Stock Forecast, Price & News $2.00 +0.02 (+1.01%) (As of 09/20/2023 ET) Add Compare Share Share Today's Range$1.98▼$2.0350-Day Range$1.98▼$2.2752-Week Range$1.85▼$3.15Volume450,816 shsAverage Volume566,671 shsMarket Capitalization$335.12 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Arbutus Biopharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside200.0% Upside$6.00 Price TargetShort InterestBearish3.09% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.43) to ($0.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.39 out of 5 starsMedical Sector911th out of 961 stocksPharmaceutical Preparations Industry435th out of 455 stocks 3.5 Analyst's Opinion Consensus RatingArbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Arbutus Biopharma has a forecasted upside of 200.0% from its current price of $2.00.Amount of Analyst CoverageArbutus Biopharma has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.09% of the outstanding shares of Arbutus Biopharma have been sold short.Short Interest Ratio / Days to CoverArbutus Biopharma has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Arbutus Biopharma has recently increased by 0.78%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldArbutus Biopharma does not currently pay a dividend.Dividend GrowthArbutus Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABUS. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 4 people have searched for ABUS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.40% of the stock of Arbutus Biopharma is held by insiders.Percentage Held by InstitutionsOnly 39.52% of the stock of Arbutus Biopharma is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arbutus Biopharma are expected to decrease in the coming year, from ($0.43) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arbutus Biopharma is -4.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arbutus Biopharma is -4.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArbutus Biopharma has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arbutus Biopharma (NASDAQ:ABUS) StockArbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Read More ABUS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABUS Stock News HeadlinesSeptember 7, 2023 | marketbeat.com3 Stocks to Buy For the COVID Resurgence (ABUS)The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be votingSeptember 13, 2023 | americanbankingnews.comArbutus Biopharma (NASDAQ:ABUS) Receives Buy Rating from HC WainwrightSeptember 21, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 12, 2023 | finance.yahoo.comArbutus (ABUS) to Focus on Hepatitis B Candidates, Stock UpSeptember 12, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Roche Holding AG (OtherRHHVF) and Arbutus Biopharma (ABUS)September 12, 2023 | markets.businessinsider.comChardan Capital Remains a Buy on Arbutus Biopharma (ABUS)September 11, 2023 | seekingalpha.comArbutus ends development of COVID, hepatitis b candidatesSeptember 11, 2023 | benzinga.comArbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway ExtendedSeptember 21, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 7, 2023 | finance.yahoo.comArbutus to Participate in Two Upcoming Investor ConferencesAugust 26, 2023 | finance.yahoo.comArbutus Biopharma (NASDAQ:ABUS) shareholders have endured a 78% loss from investing in the stock five years agoAugust 8, 2023 | markets.businessinsider.comRobert W. Baird Remains a Hold on Arbutus Biopharma (ABUS)August 4, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Arbutus Biopharma (ABUS)August 4, 2023 | finance.yahoo.comArbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2023 Earnings Call TranscriptAugust 3, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Lantheus (LNTH), Arbutus Biopharma (ABUS)August 3, 2023 | markets.businessinsider.comJMP Securities Sticks to Its Buy Rating for Arbutus Biopharma (ABUS)August 3, 2023 | finance.yahoo.comArbutus Reports Second Quarter 2023 Financial Results and Corporate UpdateAugust 3, 2023 | finance.yahoo.comArbutus Reports Second Quarter 2023 Financial Results and Corporate UpdateJuly 23, 2023 | finance.yahoo.comArbutus Biopharma Corporation (NASDAQ:ABUS) has caught the attention of institutional investors who hold a sizeable 38% stakeJuly 20, 2023 | finance.yahoo.comArbutus to Report Second Quarter 2023 Financial Results and Provide Corporate UpdateJuly 12, 2023 | finanznachrichten.deArbutus Biopharma Corporation: Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of DirectorsJuly 12, 2023 | finance.yahoo.comArbutus Appoints Melissa V. Rewolinski, PhD to its Board of DirectorsJuly 7, 2023 | msn.comJMP Securities Reiterates Arbutus Biopharma (ABUS) Market Outperform RecommendationJuly 6, 2023 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on Arbutus Biopharma (ABUS)June 22, 2023 | markets.businessinsider.comChardan Capital Sticks to Its Buy Rating for Arbutus Biopharma (ABUS)June 21, 2023 | finanznachrichten.deArbutus Biopharma Corporation: Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023June 21, 2023 | finance.yahoo.comArbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023See More Headlines Receive ABUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ABUS Company Calendar Last Earnings8/03/2023Today9/21/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABUS CUSIPN/A CIK1447028 Webwww.arbutusbio.com Phone(267) 469-0914Fax604-419-3201Employees96Year Founded1992Price Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+200.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,460,000.00 Net Margins-309.89% Pretax Margin-309.89% Return on Equity-52.00% Return on Assets-38.02% Debt Debt-to-Equity RatioN/A Current Ratio6.47 Quick Ratio6.47 Sales & Book Value Annual Sales$39.02 million Price / Sales8.59 Cash FlowN/A Price / Cash FlowN/A Book Value$0.91 per share Price / Book2.20Miscellaneous Outstanding Shares167,560,000Free Float158,509,000Market Cap$335.12 million OptionableOptionable Beta2.14 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. William H. Collier (Age 63)Pres, CEO & Director Comp: $933.01kMr. Michael J. McElhaugh (Age 49)COO & Chief Bus. Officer Comp: $606.62kDr. Michael J. Sofia Ph.D. (Age 65)Chief Scientific Officer Comp: $628.43kMr. David C. Hastings CPA (Age 62)CFO & Chief Accounting Officer Ms. Lisa M. CaperelliVP of Investor RelationsMr. J. Christopher Naftzger BA (Age 56)Esq., J.D., Gen. Counsel & Chief Compliance Officer Dr. Karen Sims M.D.Ph.D., Chief Medical OfficerMr. R. Hector Mackay-Dunn B.A. (Age 72)J.D., L.L.B., Q.C, Q.C., Sec. More ExecutivesKey CompetitorsApollomicsNASDAQ:APLMPrecigenNASDAQ:PGENSIGA TechnologiesNASDAQ:SIGAKalVista PharmaceuticalsNASDAQ:KALVTerns PharmaceuticalsNASDAQ:TERNView All CompetitorsInstitutional OwnershipNuveen Asset Management LLCBought 19,266 shares on 8/16/2023Ownership: 0.175%Goldman Sachs Group Inc.Sold 48,477 shares on 8/15/2023Ownership: 0.133%Alliancebernstein L.P.Bought 26,870 shares on 8/15/2023Ownership: 0.050%Wells Fargo & Company MNBought 27,381 shares on 8/15/2023Ownership: 0.033%Citadel Advisors LLCBought 12,100 shares on 8/15/2023Ownership: 0.000%View All Institutional Transactions ABUS Stock - Frequently Asked Questions Should I buy or sell Arbutus Biopharma stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABUS shares. View ABUS analyst ratings or view top-rated stocks. What is Arbutus Biopharma's stock price forecast for 2023? 3 equities research analysts have issued 1-year price objectives for Arbutus Biopharma's shares. Their ABUS share price forecasts range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 200.0% from the stock's current price. View analysts price targets for ABUS or view top-rated stocks among Wall Street analysts. How have ABUS shares performed in 2023? Arbutus Biopharma's stock was trading at $2.33 at the beginning of 2023. Since then, ABUS shares have decreased by 14.2% and is now trading at $2.00. View the best growth stocks for 2023 here. When is Arbutus Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our ABUS earnings forecast. How were Arbutus Biopharma's earnings last quarter? Arbutus Biopharma Co. (NASDAQ:ABUS) issued its quarterly earnings data on Thursday, August, 3rd. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.02. The biopharmaceutical company had revenue of $4.65 million for the quarter, compared to analyst estimates of $5.02 million. Arbutus Biopharma had a negative trailing twelve-month return on equity of 52.00% and a negative net margin of 309.89%. What ETFs hold Arbutus Biopharma's stock? ETFs with the largest weight of Arbutus Biopharma (NASDAQ:ABUS) stock in their portfolio include Direxion mRNA ETF (MSGR) and iShares Genomics Immunology and Healthcare ETF (IDNA).ETFMG Treatments Testing and Advancements ETF (GERM). What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO? 6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Arbutus Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX). What is Arbutus Biopharma's stock symbol? Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS." Who are Arbutus Biopharma's major shareholders? Arbutus Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.95%), Whitefort Capital Management LP (4.83%), Rubric Capital Management LP (2.03%), Hudson Bay Capital Management LP (1.70%), Geode Capital Management LLC (1.55%) and Woodline Partners LP (1.47%). View institutional ownership trends. How do I buy shares of Arbutus Biopharma? Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arbutus Biopharma's stock price today? One share of ABUS stock can currently be purchased for approximately $2.00. How much money does Arbutus Biopharma make? Arbutus Biopharma (NASDAQ:ABUS) has a market capitalization of $335.12 million and generates $39.02 million in revenue each year. The biopharmaceutical company earns $-69,460,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. How can I contact Arbutus Biopharma? Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The official website for the company is www.arbutusbio.com. The biopharmaceutical company can be reached via phone at (267) 469-0914, via email at ir@arbutusbio.com, or via fax at 604-419-3201. This page (NASDAQ:ABUS) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.